What are Recursion Pharmaceuticals' price targets for the next year?
5 brokers have issued twelve-month price targets for Recursion Pharmaceuticals' stock. Their forecasts range from $30.00 to $36.00. On average, they anticipate Recursion Pharmaceuticals' share price to reach $32.60 in the next year. This suggests a possible upside of 34.4% from the stock's current price.
Is rxrx stock a buy or sell?
[Read more...] According to 6 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is 32.67, which is an increase of 136.57% from the latest price. Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing N...
What is Recursion Pharmaceuticals' mailing address?
Recursion Pharmaceuticals' mailing address is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. The company can be reached via phone at 385-269-0203 or via email at [email protected].
When does Recursion Pharmaceuticals' lock-up period expire?
Recursion Pharmaceuticals' lock-up period expires on Wednesday, October 13th. Recursion Pharmaceuticals had issued 24,242,424 shares in its IPO on April 16th. The total size of the offering was $436,363,632 based on an initial share price of $18.00.
See more
Is recursion Pharmaceuticals a buy?
Recursion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.
Is RXRX a good stock to buy?
Out of 3 analysts, 1 (33.33%) are recommending RXRX as a Strong Buy, 0 (0%) are recommending RXRX as a Buy, 2 (66.67%) are recommending RXRX as a Hold, 0 (0%) are recommending RXRX as a Sell, and 0 (0%) are recommending RXRX as a Strong Sell.
When did recursion pharmaceuticals go public?
April 16, 2021All of the shares were offered by Recursion. The shares began trading on the Nasdaq Global Select Market on April 16, 2021 under the symbol "RXRX."
Is recursion Pharmaceuticals a good company?
Is Recursion Pharmaceuticals a good company to work for? Recursion Pharmaceuticals has an overall rating of 4.3 out of 5, based on over 64 reviews left anonymously by employees. 90% of employees would recommend working at Recursion Pharmaceuticals to a friend and 83% have a positive outlook for the business.
Is recursion a public company?
SALT LAKE CITY, April 16, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. ("Recursion" or "we") today announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share. Recursion is offering 24,242,424 shares of its Class A common stock.
What is simple recursion?
Recursion is the process of defining a problem (or the solution to a problem) in terms of (a simpler version of) itself. For example, we can define the operation "find your way home" as: If you are at home, stop moving. Take one step toward home. "find your way home".
Should I buy or sell Recursion Pharmaceuticals stock right now?
4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Recursion Pharmaceuticals in the last year. There are cu...
What is Recursion Pharmaceuticals' stock price forecast for 2022?
4 equities research analysts have issued twelve-month target prices for Recursion Pharmaceuticals' stock. Their forecasts range from $7.00 to $37.0...
How has Recursion Pharmaceuticals' stock price performed in 2022?
Recursion Pharmaceuticals' stock was trading at $17.13 at the beginning of 2022. Since then, RXRX shares have decreased by 56.4% and is now trading...
When is Recursion Pharmaceuticals' next earnings date?
Recursion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast...
How were Recursion Pharmaceuticals' earnings last quarter?
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) posted its earnings results on Wednesday, March, 23rd. The company reported ($0.38) EPS for the quart...
Who are Recursion Pharmaceuticals' key executives?
Recursion Pharmaceuticals' management team includes the following people: Dr. Christopher C. Gibson Ph.D. , Co-Founder, CEO & Director (Age 39,...
Who are some of Recursion Pharmaceuticals' key competitors?
Some companies that are related to Recursion Pharmaceuticals include Ablynx (ABLYF) , Abcam (ABCM) , Novavax (NVAX) , Vir Biotechnology (VIR) ,...
When did Recursion Pharmaceuticals IPO?
(RXRX) raised $306 million in an IPO on Friday, April 16th 2021. The company issued 18,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J....
What is Recursion Pharmaceuticals' stock symbol?
Recursion Pharmaceuticals trades on the NASDAQ under the ticker symbol "RXRX."
About Recursion Pharmaceuticals
3.3 Analyst's Opinion
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
Is Recursion Pharmaceuticals a buy right now?
Recursion Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
When is Recursion Pharmaceuticals' next earnings date?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recursion Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock.
How were Recursion Pharmaceuticals' earnings last quarter?
Recursion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022. View our earnings forecast for Recursion Pharmaceuticals.
What price target have analysts set for RXRX?
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.28) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.28). The firm had revenue of $2.53 million for the quarter, compared to analysts' expectations of $2.62 million.
Who are some of Recursion Pharmaceuticals' key competitors?
6 analysts have issued 12-month price targets for Recursion Pharmaceuticals' stock. Their forecasts range from $31.00 to $37.00. On average, they anticipate Recursion Pharmaceuticals' stock price to reach $33.67 in the next twelve months.
What is recursion pharmaceuticals?
Some companies that are related to Recursion Pharmaceuticals include Novavax (NVAX), Exelixis (EXEL), Halozyme Therapeutics (HALO), Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Vir Biotechnology (VIR), Ablynx (ABLYF), Abcam (ABCM), BioCryst Pharmaceuticals (BCRX), Fate Therapeutics (FATE), ImmunityBio (IBRX), SpringWorks Therapeutics (SWTX), Kodiak Sciences (KOD) and Twist Bioscience (TWST). View all of RXRX's competitors..
How much did Recursion Pharmaceuticals raise?
Recursion Pharmaceuticals is a clinical-stage biotechnology company decoding biology by integrat ing technological innovations across biology, chemistry, automation, data science, and engineering , with the goal of radically improving the lives of patients and industrializing drug discovery .
Key Data Points
Recursion Pharmaceuticals, a Phase 2-ready biotech using machine learning to develop therapies for various indications, filed on Monday with the SEC to raise up to $100 million in an initial public offe...
Environmental, Social, and Governance Rating
Primary metrics and data points about Recursion Pharmaceuticals, Inc..
How to calculate restricted stock?
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
How long are futures trading delayed?
To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. A company's dividend expressed as a percentage of its current stock price.
Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target and Consensus Rating
Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle.
Analyst Price Target Consensus
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Ratings By Month
Sign-up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Recursion Pharmaceuticals (NASDAQ:RXRX) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
